PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
Status:
Not yet recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
A galectin inhibitor that prevents viral replication of the Sars-CoV-2 virus through blocking
the specific terminal on the surface that enables the virus to enter human cells. This
inhibitor - ProLectin M is a novel substance that is given orally to individuals who have an
infection with Sars-CoV-2 or COVID19 disease. The oral tablet is chewed every hour for the
first 14 days. We hypothesise that patients receiving the active investigational product
(ProLectinM) will have a faster recovery from COVID19 compared to those receiving its
matching placebo. The trial is approved by Institutional Review Board for safety and all
participants will need to provide a written informed consent to volunteer in this trial. The
safety of ProLectin is established as the drug substance is recognised as a safe substance.
However its benefits in relieving patients from the COVID19 infection and providing the
patients faster recovery from its clinical symptoms and prevention of delayed sequelae of the
infection has not been proven yet.
Phase:
Phase 3
Details
Lead Sponsor:
Bioxytran Inc.
Collaborators:
ALKE RESEARCH PRIVATE LIMITED Research Consultancy